Newhouse Jeffrey H, Kho David, Rao Qasim A, Starren Justin
Department of Radiology, Columbia University Medical Center, 630 W 168th St., New York, NY 10032, USA.
AJR Am J Roentgenol. 2008 Aug;191(2):376-82. doi: 10.2214/AJR.07.3280.
Most studies of contrast-induced nephropathy lack controls to distinguish it from nephropathy from other causes. We assessed the frequency and magnitude of serum creatinine changes in patients not receiving iodinated contrast material to compare with creatinine changes in publications regarding contrast nephropathy.
From the electronic medical records of an academic medical center, adults with creatinine determinations on five consecutive days who had not received contrast material during the previous 10 days were identified. The first creatinine level was compared with those on subsequent days. We calculated the frequency with which these levels exceeded thresholds used to identify contrast nephropathy in previous publications.
Among 32,161 patients, more than half showed a change of at least 25% and more than two fifths, a change of at least 0.4 mg/dL. Among patients with baseline creatinine levels of 0.6-1.2 mg/dL, increases of at least 25%, 33%, and 50% occurred in 27%, 19%, and 11% of patients, respectively. Increases of 0.4, 0.6, and 1.0 mg/dL occurred in 13%, 7%, and 3% of patients. Among patients with baseline creatinine levels greater than 2.0 mg/dL, increases of at least 25%, 33%, and 50% occurred in 16%, 12%, and 7%. Increases of 0.4, 0.6, and 1.0 mg/dL occurred in 33%, 26%, and 18%. These increases were not different from the incidences of contrast nephropathy previously published.
The creatinine level increases in patients who are not receiving contrast material as often as it does in published series of patients who are receiving contrast material. The role of contrast material in nephropathy may have been overestimated.
大多数关于对比剂肾病的研究缺乏对照组以将其与其他原因引起的肾病相区分。我们评估了未接受碘化对比剂的患者血清肌酐变化的频率和幅度,以便与有关对比剂肾病的出版物中肌酐变化情况进行比较。
从一家学术医疗中心的电子病历中,识别出在过去10天内未接受对比剂且连续5天测定肌酐的成年人。将首次肌酐水平与随后几天的水平进行比较。我们计算了这些水平超过先前出版物中用于识别对比剂肾病的阈值的频率。
在32161例患者中,超过一半的患者肌酐变化至少25%,超过五分之二的患者肌酐变化至少0.4mg/dL。在基线肌酐水平为0.6 - 1.2mg/dL的患者中,分别有27%、19%和11%的患者肌酐升高至少25%、33%和50%。肌酐升高0.4mg/dL、0.6mg/dL和1.0mg/dL的患者分别为13%、7%和3%。在基线肌酐水平大于2.0mg/dL的患者中,分别有16%、12%和7%的患者肌酐升高至少25%、33%和50%。肌酐升高0.4mg/dL、0.6mg/dL和1.0mg/dL的患者分别为33%、26%和18%。这些升高与先前发表的对比剂肾病发生率无差异。
未接受对比剂的患者肌酐水平升高的情况与接受对比剂的已发表系列患者中一样常见。对比剂在肾病中的作用可能被高估了。